Researchers Announce Findings from Landmark Clinical Trial for Pediatric Crohn’s Disease
University of North Carolina Health Care SystemA significant clinical trial under the direction of Michael Kappelman, MD, MPH, professor of pediatrics at UNC School of Medicine, found that patients receiving the tumor necrosis factor inhibitor adalimumab combined with a low dose of methotrexate, a second immunosuppressant, did better than those treated with infliximab alone. Patients who received infliximab, another tumor necrosis factor inhibitor, had similar outcomes with or without methotrexate.